Anti-Phospho-eEF1A2 (Ser358) Antibody

Primary Antibodies

50470 MW

Specific for endogenous levels of the ~50 kDa eEF1A2 phosphorylated at Ser358. Immunolabeling is completely eliminated by treatment with ?-phosphatase.

EEF1A2

Eukaryotic Elongation Factor eEF1A exists in two variant forms, eEF1A1 and eEF1A2. While eEF1A1 is almost ubiquitously expressed in humans, eEF1A2 is predominantly found in heart, brain, and skeletal muscle (Knudsen et al., 1993). Expression of eEF1A2 may have a role in ovarian cancer, as its expression is drastically increased in human ovarian tumors (Anand et al., 2002). Due to differences in structural models between the two isoforms, eEF1A1 and eEF1A2 likely have variant-specific phosphorylation sites (Soares et al., 2009). Ribosome-associated JNK phosphorylates Ser-358 on eEF1A2 to promote degradation of newly synthesized polypeptides by the proteasome (Gandin et al., 2013).

10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol.

0.5-1mg/ml, actual concentration vary by lot. Use suggested dilution ratio to decide dilution procedure.

Cancer, DNA/RNA, Epigenetics and Nuclear Signaling, Oncoproteins, Oncoproteins/Suppressors, Ribosome, Transcription Factors, Translation

This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.

Boster Bio Anti-Phospho-eEF1A2 (Ser358) Antibody (Catalog # P03304). Tested in WB applications. This antibody reacts with Human, Mouse.

Brain, heart, and skeletal muscle.